nevirapine has been researched along with Adverse Drug Event in 28 studies
Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.
nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 9.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
| " We report the bioavailability and short-term safety of a novel paediatric FDC tablet of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP; 30/15/28 mg) in HIV-infected children." | 5.15 | Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children. ( Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R, 2011) |
| "Nevirapine is widely used for the treatment of HIV-1 infection; however, its chronic use has been associated with severe liver and skin toxicity." | 2.79 | Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions. ( Antunes, AM; Branco, T; Caixas, U; Harjivan, SG; Marinho, AT; Marques, MM; Monteiro, EC; Pereira, SA; Rodrigues, PM, 2014) |
| "To compare steady-state (ss) pharmacokinetic targets of nevirapine extended-release (NVP-XR) tablets once-daily (QD) with immediate-release (NVP-IR) tablet or oral suspension twice-daily in HIV-1-infected children and adolescents." | 2.79 | Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study. ( Anabwani, G; Feiterna-Sperling, C; Giaquinto, C; Königs, C; MacGregor, TR; Mensa, FJ; Mompati, K; Nguyen, T; Nuttall, J; Quinson, AM; Sabo, JP; Yong, CL, 2014) |
| "Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are acutely occurring, unpredictable, often life-threatening reactions that are a huge challenge in clinical practice." | 2.58 | [Acute life-threatening drug reactions of the skin]. ( Mockenhaupt, M, 2018) |
| " Currently, twice-a-day dosing is required for the successful application of NVP immediate release (IR), but there is potential for a more convenient once-a-day antiretroviral combination." | 2.47 | Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation. ( Parienti, JJ; Peytavin, G, 2011) |
| " We evaluated the adverse events associated with the use of zidovudine (ZDV)/lamivudine (3TC)/nevirapine (NVP) for neonatal PEP during the first 6 weeks of life." | 1.51 | Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants. ( Anugulruengkitt, S; Chokephaibulkit, K; Cressey, TR; Jantarabenjakul, W; Ounchanum, P; Pancharoen, C; Punnahitanon, S; Puthanakit, T; Sophonphan, J; Srirompotong, U; Suntarattiwong, P, 2019) |
| "Stavudine was prescribed to 5." | 1.40 | Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database. ( Boettiger, DC; Chaiwarith, R; Choi, JY; Ditangco, R; Kamarulzaman, A; Kantipong, P; Kerr, S; Kiertiburanakul, S; Kumarasamy, N; Law, M; Lee, C; Li, CK; Merati, TP; Mustafa, M; Ng, OT; Oka, S; Pham, TT; Pujari, S; Ratanasuwan, W; Sohn, A; Van Kinh, N; Vonthanak, S; Wong, WW; Yunihastuti, E; Zhang, F, 2014) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| " Pressure of work and insufficient perceived benefit of side-effect recording are suspected causes." | 1.37 | Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi. ( Lungu, M; Mathews, T; Tapsfield, J; van Oosterhout, JJ, 2011) |
| "There are few studies from India documenting the adverse effects of generic HAART (Highly Active Anti-retroviral Therapy)." | 1.36 | Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India. ( Dasegowda, V; Sreenivasan, S, 2010) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 24 (85.71) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Chua, KY | 1 |
| Tey, KE | 1 |
| Ogar, CK | 1 |
| Abiola, A | 1 |
| Yuah, D | 1 |
| Ibrahim, A | 1 |
| Oreagba, IA | 1 |
| Amadi, EC | 1 |
| Adeyeye, MC | 1 |
| Oshikoya, KA | 1 |
| Fricke-Galindo, I | 1 |
| LLerena, A | 1 |
| López-López, M | 1 |
| Mockenhaupt, M | 1 |
| Awodele, O | 1 |
| Aliu, R | 1 |
| Ali, I | 1 |
| Oni, Y | 1 |
| Adeyeye, CM | 1 |
| Anugulruengkitt, S | 1 |
| Suntarattiwong, P | 1 |
| Ounchanum, P | 1 |
| Srirompotong, U | 1 |
| Jantarabenjakul, W | 1 |
| Sophonphan, J | 1 |
| Punnahitanon, S | 1 |
| Pancharoen, C | 1 |
| Cressey, TR | 2 |
| Chokephaibulkit, K | 2 |
| Puthanakit, T | 1 |
| Tapsfield, J | 1 |
| Mathews, T | 1 |
| Lungu, M | 1 |
| van Oosterhout, JJ | 1 |
| Marinho, AT | 1 |
| Rodrigues, PM | 1 |
| Caixas, U | 1 |
| Antunes, AM | 2 |
| Branco, T | 1 |
| Harjivan, SG | 1 |
| Marques, MM | 2 |
| Monteiro, EC | 1 |
| Pereira, SA | 1 |
| Fortes Déguénonvo, L | 1 |
| Diop, SA | 1 |
| Leye, MM | 1 |
| Seydi, M | 1 |
| Dieng, AB | 1 |
| Bentaleb, H | 1 |
| Diouf, A | 1 |
| Lakhe, NA | 1 |
| Ka, D | 1 |
| Cisse, VM | 1 |
| Dia Badiane, NM | 1 |
| Manga, MN | 1 |
| Ndour, CT | 1 |
| Soumaré, M | 1 |
| Diop, BM | 1 |
| Sow, PS | 1 |
| Giaquinto, C | 2 |
| Anabwani, G | 2 |
| Feiterna-Sperling, C | 2 |
| Nuttall, J | 1 |
| Mompati, K | 1 |
| Königs, C | 2 |
| Mensa, FJ | 1 |
| Sabo, JP | 2 |
| Yong, CL | 1 |
| MacGregor, TR | 1 |
| Nguyen, T | 1 |
| Quinson, AM | 1 |
| Boettiger, DC | 1 |
| Kerr, S | 1 |
| Ditangco, R | 1 |
| Merati, TP | 1 |
| Pham, TT | 1 |
| Chaiwarith, R | 1 |
| Kiertiburanakul, S | 1 |
| Li, CK | 1 |
| Kumarasamy, N | 1 |
| Vonthanak, S | 1 |
| Lee, C | 1 |
| Van Kinh, N | 1 |
| Pujari, S | 1 |
| Wong, WW | 1 |
| Kamarulzaman, A | 1 |
| Zhang, F | 1 |
| Yunihastuti, E | 1 |
| Choi, JY | 1 |
| Oka, S | 1 |
| Ng, OT | 1 |
| Kantipong, P | 1 |
| Mustafa, M | 1 |
| Ratanasuwan, W | 1 |
| Sohn, A | 1 |
| Law, M | 1 |
| Sanjeeva, GN | 1 |
| Sukanya, V | 1 |
| Pavithra, HB | 1 |
| Dodderi, SK | 1 |
| Rewari, BB | 1 |
| Govindaraj, M | 1 |
| Shivananda, S | 1 |
| Premalatha, R | 1 |
| Aslanyan, S | 1 |
| Morrow, JS | 1 |
| Barnett, BS | 1 |
| Chaweza, T | 1 |
| Tweya, H | 1 |
| Ngambi, W | 1 |
| Phiri, S | 1 |
| Hosseinipour, MC | 1 |
| Bersoff-Matcha, SJ | 1 |
| Rourke, D | 1 |
| Blank, J | 1 |
| Sreenivasan, S | 1 |
| Dasegowda, V | 1 |
| Parienti, JJ | 1 |
| Peytavin, G | 1 |
| Novais, DA | 1 |
| da Silva, JL | 1 |
| Santos, PP | 1 |
| Oliveira, MC | 1 |
| Beland, FA | 1 |
| Capparelli, E | 1 |
| Sirisanthana, V | 1 |
| Muresan, P | 1 |
| Hongsiriwon, S | 1 |
| Ngampiyaskul, C | 1 |
| Limwongse, C | 1 |
| Wittawatmongkol, O | 1 |
| Aurpibul, L | 1 |
| Kabat, B | 1 |
| Toye, M | 1 |
| Smith, ME | 1 |
| Eksaengsri, A | 1 |
| McIntosh, K | 1 |
| Yogev, R | 1 |
| Eluwa, GI | 1 |
| Badru, T | 1 |
| Agu, KA | 1 |
| Akpoigbe, KJ | 1 |
| Chabikuli, O | 1 |
| Hamelmann, C | 1 |
| Mudzviti, T | 1 |
| Sibanda, M | 1 |
| Gavi, S | 1 |
| Maponga, CC | 1 |
| Morse, GD | 1 |
| Haddow, LJ | 1 |
| Wood, CW | 1 |
| Ainsworth, JG | 1 |
3 reviews available for nevirapine and Adverse Drug Event
| Article | Year |
|---|---|
An update on HLA alleles associated with adverse drug reactions.
Topics: Alleles; Allopurinol; Carbamazepine; Dideoxynucleosides; Drug-Related Side Effects and Adverse React | 2017 |
[Acute life-threatening drug reactions of the skin].
Topics: Allopurinol; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Drug-R | 2018 |
Nevirapine once daily: pharmacology, metabolic profile and efficacy data of the new extended-release formulation.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Delayed-Action Preparations; D | 2011 |
4 trials available for nevirapine and Adverse Drug Event
| Article | Year |
|---|---|
Differences in nevirapine biotransformation as a factor for its sex-dependent dimorphic profile of adverse drug reactions.
Topics: Adult; Anti-HIV Agents; Biotransformation; Drug-Related Side Effects and Adverse Reactions; Female; | 2014 |
Steady-state pharmacokinetics of nevirapine extended-release tablets in HIV-1-infected children and adolescents: an open-label, multiple-dose, cross-over study.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Over Studies; Dela | 2014 |
Nevirapine extended-release formulation tablets in HIV-1-infected children--long-term follow-up.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Delayed-Action Preparations; Drug-Related Side | 2015 |
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weig | 2011 |
21 other studies available for nevirapine and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Cutaneous adverse drug reactions among people living with human immunodeficiency virus in a tertiary care hospital in Johor, Malaysia.
Topics: Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infection | 2022 |
A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Anemia; Anti-HIV Agents; Anti-Retroviral Agent | 2019 |
Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2018 |
Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.
Topics: Anti-Retroviral Agents; Chemoprevention; Drug Therapy, Combination; Drug-Related Side Effects and Ad | 2019 |
Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care Facilities; Anti-HIV Agents; Cross-S | 2011 |
[Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; | 2013 |
Trends in first-line antiretroviral therapy in Asia: results from the TREAT Asia HIV observational database.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asia; Dideoxynucleosides; Drug-Relate | 2014 |
Nevirapine-related adverse events among children switched from efavirenz to nevirapine as compared to children who were started on nevirapine-based antiretroviral therapy directly.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes | 2015 |
Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, Malawi.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Therapy | 2016 |
Evaluation of the safety of nevirapine therapy during pregnancy.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Drug-Related Side Effects and Adverse Reactions; Female; HI | 2010 |
Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug-Related Side Effects an | 2010 |
Synthesis and oxidation of 2-hydroxynevirapine, a metabolite of the HIV reverse transcriptase inhibitor nevirapine.
Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV Revers | 2011 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cycloprop | 2012 |
Implementing a pharmacovigilance program to evaluate cutaneous adverse drug reactions in an antiretroviral access program.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Databases, Factual; Drug-Related Side Effects and Ad | 2012 |
Discontinuation of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy due to nucleoside analogue reverse transcriptase inhibitor-related metabolic toxicity.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyt | 2007 |